Elucid

Company profile

About Elucid

Elucid is an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions. The company's flagship product, Plaque-IQ, is the first and only FDA-cleared, non-invasive plaque analysis based on objective ground-truth histology rather than subjective CCTA visual estimates. Developed in partnership with world-renowned cardiovascular pathologists, Plaque-IQ quantifies and classifies plaque morphology including lipid-rich necrotic core, calcified, and non-calcified components at the patient, vessel, and lesion level. The technology addresses a critical gap in cardiovascular diagnostics: while about half of Americans between ages 45 and 84 have atherosclerosis, many don't know it, and current diagnostics miss key information about plaque type and composition. Elucid's CT Virtual Histology technology enables physicians to understand plaque tissue histology through non-invasive testing, supporting clinical decisions around intervention versus drug therapy and helping to prevent heart attacks and strokes. The company serves cardiologists, radiologists, and cardiovascular specialists across health systems and has achieved significant commercial milestones including Category I CPT code designation and broad CMS reimbursement. Elucid is also developing FFR CT capabilities that leverage histology-based plaque composition for lesion-level fractional flow reserve measurements.

Company description · Elucid official website